Carlina, Atlangram Partner On Osteoarticular Infectious Diseases Antibiotics
By Cyndi Root
Carlina Technologies has partnered with Atlangram to develop innovative antibiotics for osteoarticular infectious diseases. The companies announced the deal in a press release, stating that Atlangram also has an option for Carlina’s lipid nanocapsule technology platform SOLUDOTS. Olivier Meyer, President and CEO of Carlina, said, “Therapies for osteoarticular infectious diseases are strongly affected by increased bacterial resistance, and this will be a key market to spearhead nanoantibiotics.”
SOLUDOTS
Carlina loads millions of antibiotic molecules inside a single nanocapsule. Preliminary models show that the technology is safe and effective. One study showed that antibiotic delivery with SOLUDOTS was more effective than treatment with a “free antibiotic,” and the technology may reduce bacterial resistance. Additionally, tissue irritation was reduced. Carlina states that the nanocapsule may be loaded with multiple types of antibiotics for simultaneous delivery. The company hopes that it can give existing antibiotics a new life and find new drugs with its new partner Atlangram.
Antibiotic Market
Due to antibiotic resistance, few drugs have been approved in recent years and an estimated 50,000 people die in the U.S. and the EU due to serious bacterial infection. Carlina and Atlangram are competing in a market estimated to be worth over $60 billion in 2014, according to Carlina. A report from Transparency Markets Research states that the market will be worth $44 billion by 2016.
Report authors state that two variables will affect the market in the future: antibiotic resistance and generic competition. Due to patent expirations, brand antibiotics will have restricted growth, and due to antibiotic resistance, many drugs will face declining sales. In the antibiotics area, major players are pharmaceutical giants such as Bristol-Myers Squibb, Cubist, Takeda, and Sanofi-Aventis among others.